These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
50. Use of a thrombopoietin receptor agonist in von Willebrand disease type 2B (p.V1316M) with severe thrombocytopenia and intracranial hemorrhage. Espitia O; Ternisien C; Agard C; Boisseau P; Denis CV; Fouassier M Platelets; 2017 Jul; 28(5):518-520. PubMed ID: 27885890 [TBL] [Abstract][Full Text] [Related]
51. Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia. Hayes S; Mudd PN; Ouellet D; Johnson BM; Williams D; Gibiansky E Cancer Chemother Pharmacol; 2013 Jun; 71(6):1507-20. PubMed ID: 23564375 [TBL] [Abstract][Full Text] [Related]
52. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation. Liesveld JL; Phillips GL; Becker M; Constine LS; Friedberg J; Andolina JR; Milner LA; DeBolt J; Smudzin T; Hyrien O; Erickson-Miller CL; Johnson BM; Dawson KL; Chen Y Biol Blood Marrow Transplant; 2013 Dec; 19(12):1745-52. PubMed ID: 24120380 [TBL] [Abstract][Full Text] [Related]
56. Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation. Fattizzo B; Levati G; Cassin R; Barcellini W Drugs; 2019 Aug; 79(12):1305-1319. PubMed ID: 31292909 [TBL] [Abstract][Full Text] [Related]
57. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043 [TBL] [Abstract][Full Text] [Related]
58. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia. Alvarez Román MT; Fernández Bello I; Arias-Salgado EG; Rivas Pollmar MI; Jiménez Yuste V; Martín Salces M; Butta NV Thromb Haemost; 2014 Jul; 112(1):65-72. PubMed ID: 24500066 [TBL] [Abstract][Full Text] [Related]
59. [Retrospective analysis of eltrombopag for the treatment of refractory primary immune thrombocytopenia in Japan]. Yoshida M; Kanashima H; Nakao T; Ogawa Y; Hino M; Nakane T; Ohta T; Kumura T; Manabe M; Yamamura R; Yamane T Rinsho Ketsueki; 2013 May; 54(5):444-50. PubMed ID: 23727682 [TBL] [Abstract][Full Text] [Related]
60. A low birth weight infant with no malformations delivered by a primary immune thrombocytopenia patient treated with eltrombopag. Suzuki N; Hiraga J; Hariyama Y; Takagi Y; Ohashi H; Kishigami Y; Oguchi H; Kagami Y Int J Hematol; 2018 Jul; 108(1):109-111. PubMed ID: 29188582 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]